Thread by @Phari

#ASCO21 MM abstracts of note in no particular order with my thoughts
@mtmdphd @End_myeloma @bhemato @BldCancerDoc @adsouza_md

Frigault et al. ddBCMA – novel nonscFV binding enabled CAR-T (ARC-101) – 100% ORR (N-10)
meetinglibrary.asco.org/record/195469/… Promising and new CARs will give bispecifics a run for their money.

Berdeja et al Talquetamab truly novel GPRC5D bispecific – N-172 and RP2D established for SC; CRS 75%; skin; nail effects and dysgeusia. ORR 65%; 50% VGPR and even in pentarefr
meetinglibrary.asco.org/record/195432/…

Krishnan et al. Teclistamab N-156 ; largest BCMA bispecific dataset. RP2D for SC dose; CRS G1-2 only; 65% ORR and MDOR NR; 9/14 CRs – MRD neg. Also note #8006 elranatamab. meetinglibrary.asco.org/record/195433/…

Moreau et al. Cassiopeia Dvs.OBS Maint- All pts either. D+/-VTD then Tx the D+/-Td consolidn. MPFS D>OBS (NRv47m) but benefit only in prior D naïve SPM 5.5% in D
If D indn is Dara maint useful? Need R v. D maint in prior D exposed? meetinglibrary.asco.org/record/195428/…

Kaiser et al UHRMM/PCL; D-CVRD pentad-> AHCT then DVRD -> DR maint. MUKnine trial. 83% ORR; early PDs and PCL<<UHRMM – 22% PD at D100 post AHCT for PCL. Disappointing despite “kitchen sink” approach? meetinglibrary.asco.org/record/195431/…

Yong et al. Auto vs. KCDx 4 consolidation then K maint UK CARDAMON trial. MRD neg AHCT>>KCD; Med PFS similar (NR.vs.3.8y for KCD) HR <<SR. Time to think of immune approaches for HRMM ??meetinglibrary.asco.org/record/195429/…

Other notable – Massfix vs. tradition resp/ Bespoke ctDNA vs. flow MRD/Ciltacel update/Forte & Andromeda updates/ BMT CTN AlloHCT in MM/ Ciltacel in 1-3 prior LOT – See Abstracts # 8009/8029/8005/8002/8003/7003/8013